-
Many pharmaceutical companies transfer subsidiaries!
Time of Update: 2022-01-01
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
(hereinafter referred to as "Jinhua Kangenbei"), a subsidiary of Conba Holdings It is planned to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
-
Chengdu Beite exerts its strength!
Time of Update: 2022-01-01
At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.
-
CSPC will win 2 billion large varieties
Time of Update: 2021-12-30
Source: official website of the State Food and Drug Administration, Mi Nei. com database A few days ago, the official website of the State Food and Drug Administration showed that CSPC Ouyi Pharmaceutical's parecoxib sodium for injection has entered the administrative examination and approval stage with imitation of category 4 products .
-
The entry of Jiangsu pharmaceutical companies has soared by more than 200%.
Time of Update: 2021-12-30
A few days ago, the official website of CDE showed that Jiangsu Deyuan Pharmaceutical's Enpagliflozin tablets were accepted for listing applications submitted for imitations in 4 categories .
-
Roche Announces Interim Analysis Results of Phase 3 HAVEN 6 Study of Eimexizumab
Time of Update: 2021-12-28
HAVEN 6 is a phase 3 study conducted in patients with moderate or mild hemophilia A without factor VIII inhibitors in the body to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of Hemlibra .
-
Deqi Pharma announces Phase Ib study data of Celiniso in the treatment of T and NK cell lymphoma at the ASH annual meeting
Time of Update: 2021-12-27
Deck Pharmaceuticals Co. , Ltd. (abbreviated as "Decki Pharmaceuticals", Hong Kong Stock Exchange stock code: 6996. HK) announced today that the company will hold an offline and online combination i
-
BeiGene announced the latest clinical trial data on the safety and effectiveness of Baiyueze (Zebutinib) in the treatment of patients with relapsed/refractory B-cell malignancies who are intolerant to BTK inhibitors
Time of Update: 2021-12-27
The data of this trial shows that Baiyueze® treatment is well tolerated and is unlikely to cause the recurrence of intolerable AE events that have occurred in previous BTK inhibitor treatments At the same time, Baiyueze® is also effective in maintaining or improving the remission from baseline at least, which indicates that Baiyueze® may become a treatment option for patients with hematological malignancies who are intolerant to other BTK inhibitor treatments .
-
Boan Bio's anti-PD-L1/TGF-β innovative double antibody BA1201 was approved for clinical use
Time of Update: 2021-12-27
Luye Pharmaceutical Group announced that the anti-PD-L1/TGF-β bispecific antibody BA1201 independently developed by its holding subsidiary Boan Biologics has been approved by the Drug Evaluation Center of the China National Medical Products Administration to conduct clinical trials .
-
TJBio announces that its bispecific antibody TJ-CD4B has been approved for Phase 1 clinical trials in China
Time of Update: 2021-12-27
On December 16, 2021, Horizon Biotech announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has officially approved the bispecific antibody TJ-CD4B (also known as ABL111) for the treatment of solid tumors (including gastric cancer, Phase 1 clinical study of esophageal-gastric junction adenocarcinoma, esophageal adenocarcinoma and pancreatic duct adenocarcinoma .
-
Yangtze River Chinese Medicine Class 1 New Medicine Fascinates This 1 Billion Variety Will Meet Its Strong Enemy
Time of Update: 2021-12-27
Table 1: 2021E entity pharmacy Chinese patent medicine intestinal medicine TOP5 varieties Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern In recent years, the sales of Changyanning in physical pharmacies in Chinese cities have steadily increased, and it is expected to become a new species exceeding 1 billion in 2021.
-
BeiGene announced at the 63rd ASH Annual Meeting the research results of Baiyueze as the first-line treatment of chronic lymphocytic leukemia in the SEQUOIA trial
Time of Update: 2021-12-27
The results include: In addition, the effectiveness of cohort 2 (group C) Baiyueze® monotherapy with del (17p) patients was reported in the ASH annual meeting under the condition of extended follow-up period .
-
Qilu wins 1 billion injection of recombinant human follicle stimulating hormone injection
Time of Update: 2021-12-25
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
-
Eli Lilly's IL-23 inhibitor lebrikizumab successfully treats atopic dermatitis Phase 3 study
Time of Update: 2021-12-25
On December 21, Eli Lilly announced the data of the third key phase 3 clinical study ADhere, the IL-23 targeted monoclonal antibody lebrikizumab for the treatment of moderate to severe AD patients .
-
5 latest developments in Fragment Drug Discovery (FBDD)
Time of Update: 2021-12-25
Researchers used computational methods to design molecular fragments, link them together, and bind to different positions of SARS-CoV-2-M at the same time, and then screened a library of nearly 200,000 fragments targeting the protease binding cavity, any combination Adjacent high-affinity fragments will be connected to generate the final new candidate molecule .
-
Livzon re-attacks chemical drugs and innovative drugs, anti-tumor class 1 new drugs are coming
Time of Update: 2021-12-25
Hospital hospital hospital pharmacy pharmacy pharmacy Medical insurance negotiations have gradually formed a "one-year talk" model, and the time for innovative drugs to enter medical insurance has been greatly shortened .
-
2 billion analgesics!
Time of Update: 2021-12-24
Data source: Mi Neiwang database, NMPA On December 22, the official website of NMPA showed that Shanxi Pude Pharmaceutical Co.
Data source: Mi Neiwang database, NMPA On December 22, the official website of NMPA showed that Shanxi Pude Pharmaceutical Co.
-
Shandong New Era is showing its power!
Time of Update: 2021-12-24
Data source: Mi Neiwang database, NMPA On December 22, the official website of NMPA showed that Shandong New Times Pharmaceutical was approved to market with imitation 4 types of ivabradine hydrochloride tablets, making it the third domestic manufacturer .
-
Kelun grabs the first to imitate a rival!
Time of Update: 2021-12-09
Figure 1: The latest products declared by Fujian Shengdi Pharmaceutical Source: CDE official website ω-3 fish oil medium-long-chain fat emulsion/amino acid (16)/glucose (30%) injection is a three-chamber bag parenteral nutrition solution.
-
2.4 billion large varieties of somatostatin!
Time of Update: 2021-12-09
Data source: Mi Neiwang database On November 5, the official website of NMPA showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic company to pass the evaluation .
-
Hepatitis medicine king won the global $100 variety to attack the tens of billions of chemical medicine market
Time of Update: 2021-12-09
Figure 2: 2021E China's urban physical pharmacies TOP 20 manufacturers of proprietary Chinese medicines for liver disease Source: Mi Nei. com, China's urban physical pharmacy terminal layout Pien Tze Huang Pharmaceutical has become a dominant player in the retail market through its comprehensive channel layout and experience store models .
